Coherus BioSciences Reports on Shareholder Vote Matters
Ticker: CHRS · Form: 8-K · Filed: Jun 4, 2024 · CIK: 1512762
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: CHRS
TL;DR
CHRS filed an 8-K on shareholder votes from May 29th. All good.
AI Summary
Coherus BioSciences, Inc. filed an 8-K on June 4, 2024, reporting on matters submitted to a vote of security holders on May 29, 2024. The filing details the company's corporate structure and its principal executive offices located at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065.
Why It Matters
This filing provides transparency regarding decisions made by Coherus BioSciences' security holders, which can impact the company's strategic direction and governance.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of matters voted on by shareholders and does not indicate any immediate financial or operational risks.
Key Players & Entities
- Coherus BioSciences, Inc. (company) — Registrant
- 333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065 (location) — Principal executive offices
- May 29, 2024 (date) — Date of earliest event reported
- June 4, 2024 (date) — Date of report
FAQ
What specific matters were submitted to a vote of security holders?
The filing states that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on May 29, 2024.
What is the principal executive office address for Coherus BioSciences, Inc.?
The principal executive office is located at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065.
What is the SEC file number for Coherus BioSciences, Inc.?
The SEC file number is 001-36721.
What is the IRS Employer Identification Number for Coherus BioSciences, Inc.?
The IRS Employer Identification Number is 27-3615821.
Filing Stats: 648 words · 3 min read · ~2 pages · Grade level 10.8 · Accepted 2024-06-04 16:05:13
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share CHRS The Nasdaq
Filing Documents
- chrs-20240529x8k.htm (8-K) — 67KB
- 0001558370-24-008898.txt ( ) — 192KB
- chrs-20240529.xsd (EX-101.SCH) — 4KB
- chrs-20240529_def.xml (EX-101.DEF) — 3KB
- chrs-20240529_lab.xml (EX-101.LAB) — 16KB
- chrs-20240529_pre.xml (EX-101.PRE) — 10KB
- chrs-20240529x8k_htm.xml (XML) — 5KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders Coherus BioSciences, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting") on May 29, 2024 virtually via the Internet. At the close of business on April 9, 2024, the record date, there were 113,498,415 shares of the Company's common stock outstanding with each such share being entitled to one vote per share. At the Annual Meeting, 80,526,896 shares of the Company's common stock were voted in person or by proxy for the four proposals set forth below, each of which is described in the Company's Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 15, 2024. Proposal 1. The Company's stockholders elected by a majority of votes cast each of the Class I director nominees below, Lee N. Newcomer, MD, Charles W. Newton and Kimberly J. Tzoumakas, to the Board to hold office until the 2027 annual meeting of stockholders or until their successors are elected. BROKER NOMINEE FOR WITHHELD NON- VOTES Lee N. Newcomer, MD 48,281,843 10,274,659 21,970,394 Charles W. Newton 47,197,934 11,358,568 21,970,394 Kimberly J. Tzoumakas 46,098,866 12,457,636 21,970,394 Proposal 2. The Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024. BROKER FOR AGAINST ABSTAIN NON-VOTES 79,827,737 551,990 147,169 0 Proposal 3. The Company's stockholders approved a non-binding, advisory resolution to approve the compensation of the Company's named executive officers (a "Say-on-Pay" vote). BROKER FOR AGAINST ABSTAIN NON-VOTES 40,280,182 16,457,046 1,819,274 21,970,394 Proposal 4. The Company's stockholders approved the amendment and restatement of the Company's 2014 Equity Incentive Award Plan. BROKER FOR AGAINST ABSTAIN NON-VOTES 37,628,123 18,905,881 2,022,498 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 4, 2024 COHERUS BIOSCIENCES, INC. By: /s/ Dennis M. Lanfear Name: Dennis M. Lanfear Title: Chief Executive Officer